



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

August 23, 2019

To,
Manager – Listing
National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra–Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Clarification -NATCOPHARM - Reg.
Ref: Email received on August 22, 2019

With reference to the email received on August 22, 2019 and also with reference to the outcome of Board Meeting held on August 9, 2019, please find attached herewith the disclosure under Regulation 30 and sub-para (1) of para (A) of Part (A) of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Encl: as above

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

1) OMRV Hospitals Private Limited

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	1) Name of the target entity OMRV Hospitals Private Limited 2) Details in brief such as size, turnover etc. OMRV Hospitals Pvt Ltd is engaged in the running of a hospital by the brand name "Pace Hospital" in Hyderabad, Telangana. In FY 2017-18, the revenue was INR 25.04 crores.
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Health Care (Hospitals and Clinic)
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To support entrepreneurship and development of viable healthcare in Hyderabad
E	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
F	Indicative time period for completion of the acquisition;	September 30, 2019
G	Nature of consideration - whether cash consideration or share swap and details of the same	5,00,000 0.05% Compulsory Convertible Cumulative Preference Shares (CCCPS) of Rs.100/- each
H	Cost of acquisition or the price at which the shares are acquired	Rs.5,00,00,000 (Rupees Five Crores only)
I	Percentage of shareholding / control acquired and / or number of shares acquired	Increase from the present 9.29% to 12.81% of the shares on a fully diluted basis of OMRV Hospitals Private Limited

mtw



Sl. No.	Particulars	Details of Investment
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	1. Brief background: OMRV Hospitals Pvt Ltd is engaged in the running and administration of hospital & clinic. Currently, it's operating one hospital in Hyderabad. 2. Line of business: Health Care (Hospitals and Clinic) 3. Date of incorporation: 23rd September, 2011 4. Turnover of last 3 years (in Rupees): For the FY 2017-18: 25,04,21,376 For the FY 2016-17: 17,03,94,195 For the FY 2015-16: 14,14,45,627 5. Country in which the acquired entity has presence: India

MATW



2) AACT, Inc. (AACT)

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	1) Name of the target entity AACT, Inc. (AACT), USA 2) Details in brief such as size, turnover etc. It is the first year of operation.
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
C	Industry to which the entity being acquired belongs	Pharmaceutical Research
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To support R&D and development of oncological products
E	Brief details of any governmental or regulatory approvals required for the acquisition	Reserve Bank of India
F	Indicative time period for completion of the acquisition;	March 31, 2020
G	Nature of consideration - whether cash consideration or share swap and details of the same	Around 250 Common stock of \$0.001
H	Cost of acquisition or the price at which the shares are acquired	An amount around US\$ 250,000 (US Dollars Two hundred Fifty Thousand only)
I	Percentage of shareholding / control acquired and / or number of shares acquired	Around 6.25% of the shares on a fully diluted basis of AACT, Inc.

NATCO



Sl. No.	Particulars	Details of Investment
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	1. Brief background: AACT has identified certain proprietary biotechnology including certain pre-clinical pharmaceutical compound(s) and wishes to conduct the pre-clinical development of these drugs. 2. Line of business: Pharmaceutical Research 3. Date of incorporation: November 8, 2018 4. Turnover of last 3 years: Nil 5. Country in which the acquired entity has presence: USA

MAN

